

## CASE REPORT:

### Diabetic Wound Patient Highly Responsive to ProgenaMatrix®

#### Case

Here we present a chronic foot wound in an 81-year-old male patient that was complicated by diabetes, poor nutrition, poor local perfusion, and medical non-compliance. The patient received various standard chronic wound treatments with little response and was considering below the knee amputations.

#### Diabetic Foot Ulcers Right – Heel from Pressure Injury/Decubitus Ulcer

**Vascularity:** PT 1/4, DP 1/4


**Comorbidities:** History of stroke, limited mobility, COPD, Type 2 diabetes, hypertension. Currently on Insulin, Metformin, Anticoagulants

#### Prior treatment includes:

- 2021 – January to April: Amniotic Membrane Graft for 6 weeks; wound reduced but not closed

#### CASE REPORT:

- 2021 – June to August: ProgenaMatrix®; 5.3x3.6 cm (8 weeks to full closure)



#### Outcomes

In this work, we report our success with ProgenaMatrix, a hydrogel wound covering that is the first ever human keratin-based skin substitute. When other methods for treating wounds including other skin substitutes, negative pressure therapy, and revascularization demonstrated limited success, ProgenaMatrix was applied and progress measured at regular follow-up intervals.

It is our hope that combining the science behind keratin-based skin substitutes and real patient evidence will help wound care specialists incorporate ProgenaMatrix into their arsenal of treatments for hard-to-treat wounds.

#### Results

After application of ProgenaMatrix human keratin hydrogel matrix for just one week, the chronic wound in this case series was reduced in size and visually improved. Total closure was achieved in 8 weeks.